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Abstract: The use of positron emission tomography compared with
conventional staging increases the detection of extrathoracic metas-
tases and reduces the number futile thoracotomies in patients being
evaluated for surgical resection. Long-term follow-up of one of the
two adjuvant chemotherapy trials revealed a continued overall
survival (OS) benefit to adjuvant chemotherapy. In locally advanced
non-small cell lung cancer, a phase III trial of chemoradiotherapy
alone and with surgical resection revealed no statistically significant
difference in OS between the treatment arms. In advanced stage
non-small cell lung cancer, a phase III trial compared gefitinib with
carboplatin and paclitaxel in a clinically enriched patient population
for epidermal growth factor receptor (EGFR) tyrosine kinase (TK)
mutations; among patients with an EGFR TK mutation, patients in
gefitinib arm compared with carboplatin and paclitaxel arm experi-
enced a statistically significant superior response rate and progres-
sion-free survival, and among patients without EGFR TK mutation
patients in the gefitinib arm compared with carboplatin and pacli-
taxel experienced a statistically significant inferior response rate and
progression-free survival. A phase III trial of platinum-based ther-
apy with and without cetuximab in the first-line setting revealed
improved OS in the cetuximab arm. A phase III trial of maintenance
pemetrexed compared with placebo in patients who had not pro-
gressed after initial platinum-based therapy revealed an improve-
ment in OS of patients in the pemetrexed arm with nonsquamous
histology. In limited-stage small cell lung cancer, a phase III trial
compared standard and high-dose prophylactic cranial irradiation
and revealed no significant difference in the rate of brain metastases
between the two treatment arms.
Key Words: Chemoradiotherapy, Surgical resection, Stereotactic
body radiotherapy, Epidermal growth factor receptor mutations,
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(J Thorac Oncol. 2010;5: 935–939)
The introduction of several novel agents for systemictherapy and advances in radiation and surgical techniques
has led to an increase in the number of clinical trials in lung
cancer. In addition, recognition that a subset of patients with
non-small cell lung cancer (NSCLC) is unusually responsive
to targeted agents has energized the lung cancer community
to conduct a number of interesting translational research
studies. It has become daunting for the lung cancer expert to
keep up with advances in lung cancer research as these
studies mature. We sought to provide a synopsis of clinical
trials published in peer-reviewed journals that are likely to
affect clinical care and stimulate further research in the
fields of radiation oncology, medical oncology, and tho-
racic surgery.
EARLY STAGE NSCLC
Although the use of 18-fluorodeoxyglucose (FDG)
positron emission tomography (PET) has emerged as the
standard of care in many centers for evaluation of patients
with lung cancer, evidence of benefit from randomized stud-
ies was clearly lacking till now. Maziak et al.1 published
findings demonstrating the utility of FDG-PET scan in the
evaluation of patients with stage I-IIIA NSCLC; all patients
underwent imaging for intracranial metastases and were ran-
domized to conventional staging computed tomography (CT)
and bone scan (n  167) or PET-CT (n  170). Disease was
correctly upstaged in the PET-CT and conventional staging arms
in 23 (13.8%) and 11 (6.8%) patients, respectively, and incor-
rectly upstaged in eight patients (4.8%) and one (0.6%) patient,
respectively. FDG-PET scan clearly identified more patients
with mediastinal and extrathoracic metastatic disease than con-
ventional staging although there were a number of false-positive
results with this sensitive technology. Fischer et al.2 randomized
patients to conventional staging alone (n  91) and with FDG-
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PET scans (n  98). The primary end point was the rate of
futile thoracotomies; defined as confirmed N2 mediastinal
lymph node involvement (stage IIIA), stage IIIB, or stage IV,
benign lung lesion, exploratory thoracotomy, or thoracotomy
with recurrent disease or death within 1 year after random-
ization. Among patients in the FDG-PET scan staging arm
compared with the conventional staging alone, there was a
statistically significant lower number of thoracotomies, 60
and 73 patients, respectively (p 0.004), and among patients
undergoing thoracotomies, 21 in the PET-CT and 38 in the
conventional-staging group were futile thoracotomies (p 
0.05). There was no difference in mortality between the two
treatment arms; median survival was 31 months in the
PET-CT group and 49 months in the conventional staging
group (p  0.29).
Evidence continues to emerge regarding clinical care
outcomes in specialized centers dedicated to lung cancer care.
Farjah et al.3 compared the care provided by general sur-
geons, cardiothoracic surgeons, and general thoracic surgeons
from Surveillance Epidemiology and End Results (SEER)
data of lung cancer patients undergoing pulmonary resection
for lung cancer (n  19,745). Compared with general sur-
geons and cardiothoracic surgeons, general thoracic surgeons
more frequently used PET scans (36% versus 26% versus
26%, respectively; p  0.005) and performed lymphadenec-
tomy (33% versus 22% versus 11%, respectively; p 0.001),
indicating greater use of preoperative and intraoperative stag-
ing. After adjustment for patient characteristics, disease char-
acteristics, management characteristics, hospital teaching sta-
tus, and surgeon and hospital volume, patients treated by a
general thoracic surgeon had an 11% lower hazard of death
compared with those who underwent resection by a general
surgeon (hazard ratio [HR]  0.89, 99% confidence interval
[CI]  0.82–0.97). The risks of death did not vary signifi-
cantly between cardiothoracic surgeon and general surgeon
(HR  0.94, 99% CI  0.88–1.01) or general thoracic
surgeon and cardiothoracic surgeon (HR  0.94, 99% CI 
0.87–1.03).
The past decade has seen a surge in research regarding
stereotactic body radiotherapy (SBRT) for high-risk early
stage disease. Although preliminary results demonstrate ex-
cellent local tumor control, few mature prospective studies
have been reported. The results of a phase II SBRT trial
conducted at Indiana University (IU) were recently updated
with median follow-up of 50 months.4 Seventy patients with
T1 or T2 N0 NSCLC were treated to doses of 60 to 66 Gy in
three fractions prescribed to the 80% isodose line. Local
tumor control was an impressive 88% at 3 years and median
survival was 32.4 months. Grade 3 or higher toxicity was
observed in 10% of patients with peripheral tumors and 27%
of patients with central lesions, suggesting that the regimen
be restricted to peripheral lesions. The radiation Therapy
Oncology Group 0236 used the IU regimen for peripheral
lesions in a cooperative group setting, and of 55 patients
followed up for a median 34 months, only one relapse in the
primary site has been observed.5 In addition, a phase II
multi-institutional Scandinavian SBRT study was reported
with 35-month median follow-up.6 Three-year overall sur-
vival (OS) and local tumor control for 57 eligible patients
were 60% and 92%, respectively. The estimated risk of any
failure was greater for patients with T2 lesions. Sixteen
patients developed grade 3 toxicity, although toxic deaths
were not observed. Unlike North American studies, a patho-
logic diagnosis of NSCLC was not required for protocol entry
and one-third of patients were diagnosed based only on
radiographic characteristics. These reports continue to vali-
date SBRT as an excellent treatment consideration for med-
ically inoperable patents, while at the same time highlighting
potential adverse effects. As SBRT becomes more widely
used, late effects are now being recognized. For example,
27% of patients not oxygen dependent before treatment
eventually became oxygen dependent in the phase II IU
study. A separate report from IU assessed toxicity of SBRT
for apical lung lesions and found grade 2–4 brachial plexus
toxicity in 7 of 37 patients, and the authors suggested limiting
the maximum brachial plexus dose to 26 Gy.7 The risk of
rib fracture is also increasingly recognized after SBRT, with
recent series reporting rib fractures in more than 20% of
patients with long-term follow-up.8 Dosimetric correlates for
developing rib pain and fracture have been put forward but
not yet agreed.
An alternative strategy for treating early NSCLC, ac-
celerated hypofractionated radiotherapy, was studied by the
Cancer and Leukemia Group B in one of the first prospective
multi-institutional cooperative group studies designed specif-
ically for high-risk patients with T1N0 or T2N0 (4 cm)
NSCLC.9 Thirty-nine eligible patients meeting defined crite-
ria for pulmonary dysfunction were treated with involved
field three-dimensional conformal RT (3D RT). The total
dose was kept constant at 70 Gy, whereas the number of daily
fractions in each successive cohort was reduced from 29 daily
fractions of 2.41 Gy to 17 daily fractions of 4.11 Gy. Patients
with either peripheral or centrally located lesions were eligi-
ble. Overall treatment was well tolerated; there were two
grade 3 nonhematologic toxicities and no grade 4 or greater
toxicity. With median follow-up of 53 months, three local
failures have been identified (7.7%) and median survival is
38.5 months. This experience compares well with reports of
SBRT, with less apparent severe toxicity, and suggests fur-
ther investigation of accelerated 3D radiation therapy (RT)
may be warranted.
Adjuvant chemotherapy only recently has become the
standard of care for patients with completely resected stage II
and III NSCLC with a good performance status.10 The long-
term safety and efficacy data from two adjuvant cisplatin-
based chemotherapy trials have been published. An analysis
of the International Adjuvant Trial with median follow-up of
7.5 years (n  1,867) revealed a nonstatistically significant
difference in OS of adjuvant chemotherapy compared with
observation (HR  0.91, 95% CI  0.81–1.02; p  0.10).11
There was a significant difference between OS before and
after 5 years of follow-up with patients in the chemotherapy
arm experiencing superior survival before 5 years and inferior
survival after years compared with observation; HR for be-
fore 5 years  0.86, 95% CI  0.76 to 0.97; p  0.01 versus
HR for after 5 years 1.45, 95% CI 1.02 to 2.07, p 0.04
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(p  0.006 for interaction). The analysis of non-lung cancer
deaths observed in the chemotherapy compared with the
observation arm for the whole period revealed a higher rate of
non-lung cancer deaths in the chemotherapy arm (HR 1.34,
95% CI  0.99–1.81; p  0.06). An updated analysis of
JBR-10 with a median follow-up of 9.3 years (n  482)
continued to reveal a survival benefit for chemotherapy com-
pared with observation (HR  0.78, 95% CI  0.61–0.88;
p  0.04). The observation arm was associated with a
significantly higher risk of death from lung cancer (p  0.02)
with no difference in the rate of death from other causes or
second malignancies between the arms.12
LOCALLY ADVANCED NSCLC
The Intergroup 0139 trial investigated the role of sur-
gery after concurrent chemoradiotherapy with cisplatin/eto-
poside (PE) chemotherapy compared to the concurrent che-
moradiotherapy alone for patients with stage IIIA NSCLC did
not reveal a survival benefit with the addition of surgery.13
Nevertheless, the study is important in setting the bar for
patients treated with standard dose (61 Gy) thoracic radio-
therapy and second-generation chemotherapy (22-month me-
dian survival and 20% 5-year survival). Controversy will
reign, however, given the high mortality rate for pneumonec-
tomy (as high as 29%) compared with 1% for lobectomy
and the potential influence of this on the overall study results.
Many thoracic surgical oncologists will continue to use sur-
gery for patients with resectable IIIA disease as part of a
multimodality approach despite these findings, but these
results have clearly dampened enthusiasm for surgery in all
but carefully selected patients with stage III A NSCLC.
The Radiation Therapy Oncology Group also explored
gemcitabine-based chemotherapy regimens in combination
with RT for stage III disease.14 A phase I “ping-pong” design
trial assessed the maximum tolerated dose of weekly
gemcitabine and carboplatin and weekly gemcitabine and
paclitaxel. The maximum tolerated dose of the gemcitab-
ine and carboplatin regimen was gemcitabine 450 mg/
m2/wk and carboplatin area under the curve (AUC) 2
weekly, whereas the GP arm closed early because of
toxicity at the initial dose level of gemcitabine 300 mg/m2
weekly and paclitaxel 30 mg/m2 weekly. Median survival
approximated 13 months with both regimens emphasizing
that the potential benefits of gemcitabine-based chemora-
diotherapy regimens are not likely to outweigh the risks.
METASTATIC NSCLC
EGFR TK Inhibitors
The Iressa versus Carboplatin/Paclitaxel in Asia (Iressa
Pan-Asia Study) was a phase III trial compared gefitinib with
carboplatin and paclitaxel in Asian patients with adenocarci-
noma who were light smokers (defined as 10 pack-years
and quit 15 years ago) or never smokers. The primary end
point was the noninferiority of gefitinib relative to carboplatin
and paclitaxel on progression-free survival (PFS). The trial
met the primary end point and demonstrated the superiority of
gefitinib (n  609) compared with carboplatin and paclitaxel
(n  608) (HR  0.74, 95% confidence interval (CI) 
0.65–0.85; p  0.001; median PFS of 5.7 and 5.8 months,
respectively), and higher objective response rate (RR) (43%
versus 32.2%, odds ratio 1.59, 95% CI  1.25–2.01; p 
0.001). Significantly more patients in the gefitinib arm than
those in the carboplatin and paclitaxel arm experience a
clinically relevant improvement in quality of life. OS in an
early analysis (450 patients have died [37%]) revealed similar
survival among patients in the gefitinib arm compared with
carboplatin and paclitaxel treatment arm (HR  0.91, 95%
CI  0.76–1.10; median survival of 18.6 and 17.3 months,
respectively).
Of the 1207 patients enrolled, 1038 (85.3%) provide
consent for biomarker analysis and 683 patients (56.1%)
provided tumor samples. Epidermal growth factor receptor
(EGFR) mutation analysis could be performed on 437 pa-
tients (35.9% of the total patient population), and 59.7% were
positive for an EGFR mutation. There was a significant
interaction between treatment and EGFR mutation and PFS.
In the EGFR mutation positive subgroup, the PFS was sig-
nificantly longer among patients receiving gefitinib than
among those receiving carboplatin and paclitaxel (HR 
0.48, 95% CI  0.36–0.64; p  0.001). In the EGFR
mutation negative subgroup, the PFS was significantly
shorter among patients receiving gefitinib compared with
carboplatin and paclitaxel (HR  2.85, 95% CI  2.05–3.98;
p  0.001). In the EGFR mutation positive subgroup, the
objective RR was significantly higher among patients receiv-
ing gefitinib compared with carboplatin and paclitaxel, 71.2%
and 47.3%, respectively (p  0.001). In the EGFR mutation
negative subgroup, the objective RR was significantly lower
among patients receiving gefitinib compared with carboplatin
and paclitaxel, 1.1% (one patient) and 23.5%, respectively
(p  0.001).
The Spanish Lung Cancer Group investigated screen-
ing patients with advanced stage NSCLC for EGFR mutation,
and patients who had an EGFR mutation were treated with
erlotinib 150 mg daily.15 A smoking history was obtained at
baseline, and patients were categorized as never smoker
(100 lifetime cigarettes), former smokers (1 year since
cessation), or current smokers (still smoking or1 year since
cessation). A total of 2105 pretreatment tumor samples were
collected and mutations were detected in 350 of the 2105
patients (16.6%). The frequency of EGFR mutations among
patients who were never smokers, former smokers, and cur-
rent smokers was 37.7% (95% CI  34–41.7), 9.5% (95%
CI 7.8–11.6), and 5.8% (95% CI 4.0–8.6), respectively.
The most frequently detected mutations were deletion of exon
19 (62.2%) and L858R (37.8%). The RR observed in the
intent-to-treat population was 70.6%, 19.3% of patients ex-
perienced stable and 10.2% experienced progressive disease.
The RR was significantly higher among patients with an exon
19 (n 135) than L858R (n 82; odds ratio 3.08; 95% CI
1.63–5.81; p  0.001), but no significant difference in PFS
related to type of mutation was observed. The median PFS
was 14.0 months (95% CI  11.3–16.7), and median OS was
27.0 months (95% CI  22.7–31.3) in the intent to treat
population. Median survival for patients receiving first-line
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therapy (n  113) was 28.0 months (95% CI  22.7–33) and
for those receiving second-line therapy (n  104) was 27.0
months (95% CI  19.9–34.1; p  0.67).
Antibody Against EGFR
Previous phase II trials had demonstrated activity of
single-agent cetuximab or in combination with chemothera-
py,16–18 and a randomized phase III trial investigated the
combination of cisplatin and vinorelbine with and without
cetuximab with the primary end point of improvement on OS
(n  1125).19 Patients were required to have advanced stage
disease and immunohistochemical evidence of EGFR expres-
sion in at least one positively stained tumor cell. Patients
assigned to the chemotherapy and cetuximab-containing arm
compared with the chemotherapy alone arm experienced a
longer survival (HR  0.871, 95% CI  0.762–0.996; p 
0.044; median 11.3 and 10.1 months, respectively). The RR
was higher among patients in the chemotherapy and cetux-
imab compared with chemotherapy alone, 36% versus 29%,
respectively (p  0.010), but the PFS was not different
(HR 0.943, 95% CI 0.825–1.077; p 0.39; median PFS
4.8 in both groups). No significant differences in quality of
life were observed between the two arms. A higher rate of
grade 3 or 4 febrile neutropenia was observed on the cetux-
imab arm compared with the chemotherapy-alone arm, 22%
versus 15%, respectively (p  0.0086).
Maintenance Chemotherapy
A phase III trial compared maintenance pemetrexed
with placebo in patients who had not experienced disease
progression after four cycles of platinum-based therapy. The
primary end-point of PFS and treatment with maintenance
pemetrexed compared with placebo resulted in an improve-
ment in PFS (HR  0.50, 95% CI  0.42–0.61; p  0.0001;
median PFS of 4.3 versus 2.6 months) and OS (HR  0.79,
95% CI  0.65–0.95; p  0.012; median OS of 13.4 versus
10.6 months) in the intent-to-treat patients population. The
benefit was restricted to patients with nonsquamous tumors:
PFS (HR  0.44, 95% CI  0.36–0.55, p  0.0001; median
PFS 4.5 versus 2.6 months), and OS (HR0.47, 95% CI 
0.37 to 0.60, p  0.0001; median OS 15.5 versus 10.3
months). Drug-related toxicities of 3 were significantly
higher on the pemetrexed arm, specifically fatigue (5% versus
1%) and neutropenia (3% versus 0%).
LIMITED-STAGE SMALL CELL LUNG CANCER
There has been virtually no significant progress in the
systemic therapy for small cell lung cancer (SCLC) during
the past 2 decades, as outcomes observed in the Intergroup
trial using four cycles of PE chemotherapy and concurrent 45
Gy twice-daily RT for limited stage disease have not been
eclipsed.20 Most efforts have focused on improving systemic
disease control through the study of novel systemic agents,
although local tumor relapse remains a major cause of treat-
ment failure. Tirapazamine (TPZ), a benzotriazine di-N-
oxide, has selective cytotoxicity for hypoxic cells with po-
tential radiosensitizing properties. A Southwest Oncology
Group phase II trial studied the addition of TPZ to PE
chemotherapy and 61 Gy once-daily RT.21 Seventy-two pa-
tients were accrued between 2003 and 2006, although the
study was closed early due to reports of excess toxicity with
TPZ in an external head and neck trial. Median failure-free
survival and OS were 11 and 21 months, respectively. Tox-
icity was acceptable, although esophagitis was more common
than that in previous Southwest Oncology Group studies. The
protocol recommended that the volume of total lung receiving
more than 20 Gy (V20) is less than 35%, which potentially
may have led to a favorable (low disease burden) cohort of
patients, and the results are further confounded by the use of
a nonstandard protracted thoracic RT regimen. Although the
study met the primary end point, the authors acknowledge
that hypoxic cell sensitizers with a better therapeutic index
are needed.
Improved survival with prophylactic cranial irradiation
(PCI) for patients with limited-stage SCLC after complete
response to therapy was previously demonstrated in a meta-
analysis of randomized trials. A long-term benefit from PCI
was also suggested from a recent analysis of almost 8000
patients with limited-stage SCLC in the SEER database
diagnosed between 1988 and 1997.22 On multivariate analysis
of cause-specific survival and OS, age at diagnosis, sex,
grade, extent of primary disease, size of disease, extent of
lymph node involvement, and PCI were found to be signifi-
cant. Five-year OS was 19% with PCI and 11% without PCI.
Nonetheless, the optimal dose and schedule of PCI for lim-
ited-stage SCLC has been an area of debate, with some data
suggesting higher doses of radiotherapy further reduce the
appearance of brain metastases. A multinational randomized
phase III study, comparing standard-dose PCI and high-dose
PCI, was reported by the PCI Collaborative group.23 Overall,
720 patients were randomized to either 25 Gy (in 10 frac-
tions) or 36 Gy (either 18 once-daily fractions or 24 twice-
daily fractions). Brain metastases developed in 29% of the
low-dose arm and 23% of the high-dose arm, but the differ-
ence was not significant. On the other hand, 2-year survival
significantly favored the low-dose PCI arm, 42% versus 37%.
The reason for inferior survival with high-dose PCI was not
clear, although the authors suggested that more patients in the
high-dose arm died of progressive cancer. Given this result,
the standard of care for PCI remains 25 Gy in 10 fractions.
A previously reported European Organization for Re-
search and Treatment of Cancer (EORTC) randomized phase
III study for extensive stage SCLC demonstrated reduced
symptomatic brain metastases at 1 year (40.4–14.6%) and
increased OS (13% versus 27%) at 1 year for patients ran-
domized to receive PCI after a response to chemotherapy.
Nevertheless, questions remained regarding potential toxic
effects of PCI. The outcomes of a correlative study assessing
health-related quality of life have now been reported.24 Short-
term results up to 3 months showed that there was a negative
effect of PCI on selected health-related quality of life scales,
and the largest difference between the two arms was observed
for fatigue and hair loss. The authors concluded that PCI
should be offered to all responding ED SCLC patients,
whereas patients should be informed of (and monitored for)
potential adverse effects.
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SUMMARY
In conclusion, it has become clear that the presence of
mutations in the EGFR TK domain best predicts those who
have a dramatic benefit from EGFR TK inhibitors. In our
opinion, it is best to restrict the use of EGFR TK inhibitors in
the frontline setting only to those who have an EGFR TK
mutation in the tumor. Maintenance chemotherapy with pem-
etrexed is a new option in the management of patients with
metastatic NSCLC. Surgery plays an important role in the
management of patients without mediastinal nodal involve-
ment, and the long-term safety data from postoperative adju-
vant chemotherapy are quite reassuring. There is an urgent
need to develop novel strategies to improve the outcomes of
patients with SCLC. With better understanding of genomic
alterations in lung cancer, we are confident that the pace of
progress in clinical research will accelerate and provide
meaningful improvements in patient outcomes in the future.
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